{
    "ticker": "OPTXW",
    "name": "Opthea Limited",
    "description": "Opthea Limited is a biotechnology company focused on developing innovative therapies for the treatment of eye diseases, particularly those associated with retinal diseases. Founded in 2009 and headquartered in Melbourne, Australia, Opthea aims to provide breakthrough solutions for patients suffering from conditions like wet age-related macular degeneration (AMD) and diabetic macular edema (DME). The company's lead product candidate, OPT-302, is a novel, dual-acting therapy designed to inhibit specific pathways involved in disease progression, complementing existing standard of care treatments. Opthea's research is grounded in extensive clinical trials and collaborations with leading ophthalmology experts, positioning the company as a significant player in the ophthalmic therapeutics market. With a commitment to advancing eye care, Opthea is dedicated to improving the quality of life for patients facing severe vision impairment and blindness. The company continues to explore additional therapeutic areas and expand its pipeline, guided by a vision of transforming the landscape of ocular disease treatment through science and innovation.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Melbourne, Australia",
    "founded": "2009",
    "website": "https://www.opthea.com",
    "ceo": "Dr. Megan Baldwin",
    "social_media": {
        "twitter": "https://twitter.com/OptheaLimited",
        "linkedin": "https://www.linkedin.com/company/opthea-limited/"
    },
    "investor_relations": "https://www.opthea.com/investors",
    "key_executives": [
        {
            "name": "Dr. Megan Baldwin",
            "position": "CEO"
        },
        {
            "name": "Dr. Chris W. S. Lee",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "OPT-302"
            ]
        }
    ],
    "seo": {
        "meta_title": "Opthea Limited | Innovative Therapies for Eye Diseases",
        "meta_description": "Explore Opthea Limited, a biotechnology company focused on developing treatments for retinal diseases such as wet AMD and DME. Learn about our innovative therapies and commitment to eye care.",
        "keywords": [
            "Opthea",
            "Biotechnology",
            "Ophthalmology",
            "Retinal Diseases",
            "Wet AMD",
            "Diabetic Macular Edema",
            "OPT-302"
        ]
    },
    "faq": [
        {
            "question": "What is Opthea known for?",
            "answer": "Opthea is known for developing innovative therapies for retinal diseases, particularly wet AMD and DME."
        },
        {
            "question": "Who is the CEO of Opthea?",
            "answer": "Dr. Megan Baldwin is the CEO of Opthea Limited."
        },
        {
            "question": "Where is Opthea headquartered?",
            "answer": "Opthea is headquartered in Melbourne, Australia."
        },
        {
            "question": "What is Opthea's lead product?",
            "answer": "Opthea's lead product candidate is OPT-302, designed for the treatment of retinal diseases."
        },
        {
            "question": "When was Opthea founded?",
            "answer": "Opthea was founded in 2009."
        }
    ],
    "competitors": [
        "REGN",
        "RGEN",
        "AMGN"
    ],
    "related_stocks": [
        "AAPL",
        "MSFT",
        "JNJ",
        "PFE"
    ]
}